FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches
- 2 September 2022
- journal article
- research article
- Published by Springer Nature in Frontiers of Medicine
- Vol. 16 (6) , 896-908
Abstract
Fibroblast growth factor 13 (FGF13) is aberrantly expressed in multiple cancer types, suggesting its essential role in tumorigenesis. Hence, we aimed to explore its definite role in the development of acute myeloid leukemia (AML) and emphasize its associations with bone marrow niches. Results showed that FGF13 was lowly expressed in patients with AML and that its elevated expression was related to prolonged overall survival (OS). Univariate and multivariate Cox regression analyses identified FGF13 as an independent prognostic factor. A prognostic nomogram integrating FGF13 and clinicopathologic variables was constructed to predict 1-, 3-, and 5-year OS. Gene mutation and functional analyses indicated that FGF13 was not associated with AML driver mutations but was related to bone marrow niches. As for immunity, FGF13 was remarkably associated with T cell count, immune checkpoint genes, and cytokines. In addition, FGF13 overexpression substantially inhibited the growth and significantly induced the early apoptosis of AML cells. The xenograft study indicated that FGF13 overexpression prolonged the survival of recipient mice. Overall, FGF13 could serve as an independent prognostic factor for AML, and it was closely related to the bone marrow microenvironment.Keywords
This publication has 42 references indexed in Scilit:
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapyNature Reviews Molecular Cell Biology, 2013
- Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cellsScientific Reports, 2013
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human CancerImmunity, 2013
- Fibroblast Growth Factor 13 Is a Microtubule-Stabilizing Protein Regulating Neuronal Polarization and MigrationCell, 2012
- The extracellular matrix: A dynamic niche in cancer progressionJournal of Cell Biology, 2012
- BTN1A1, the Mammary Gland Butyrophilin, and BTN2A2 Are Both Inhibitors of T Cell ActivationThe Journal of Immunology, 2010
- Phase I Trial and Pharmacokinetic Study of Raltitrexed in Children with Recurrent or Refractory Leukemia: A Pediatric Oncology Group StudyClinical Cancer Research, 2005
- Fibroblast Growth Factor (FGF) Homologous Factors Share Structural but Not Functional Homology with FGFsJournal of Biological Chemistry, 2003
- Interleukin-12 and the regulation of innate resistance and adaptive immunityNature Reviews Immunology, 2003
- Apoptosis and Mitotic Arrest Are Two Independent Effects of the Protein Phosphatases Inhibitor Okadaic Acid in K562 Leukemia CellsBiochemical and Biophysical Research Communications, 1999